Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07482761
Starting soon Observational

Multiple Myeloma t(4 ;14) FFPE Samples

NCT07482761 · tracked via the Priya Life Science France tracker
Sponsor
BIWAKO
Phase
Observational
Started
2026-07-05
Last updated
2026-03-19

Condition(s) studied

Multiple Myeloma and Malignant Plasma Cell Neoplasms

Study summary

This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.

No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients with histologically confirmed myeloma with a t(4;14) translocation * Availability of a representative FFPE block from a surgical specimen. * Diagnosis established within the past 10 years. * Availability of associated clinical and follow-up data. Exclusion Criteria: * Bone lesions samples * Insufficient or non-representative FFPE material. * Missing key diagnostic or clinical data.

Primary outcome measure(s)

  • Feasibility of cohort inclusion based on availability of FFPE tissue and confirmed myeloma disease with (4;14) translocation. — Baseline
    Number of participants who meet both criteria: - confirmation of t(4;14) disease using predefined clinical and histopathological criteria, and - availability of an adequate FFPE tissue block suitable for inclusion. Feasibility will be quantified by reporting the proportion of eligible participants among all patients screened for potential inclusion.

Trial sites (1)

FacilityCityRegionStatus
BIWAKO Lyon France

More BIWAKO trials in France

Multiple Myeloma Extramedulary Disease Samples FFPE Starting soon

Other trials for the same condition

Multiple Myeloma Extramedulary Disease Samples FFPE Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07482761 on ClinicalTrials.gov ↗ ← All trials in France